Document Detail

Acid reflux treatment for hoarseness.
MedLine Citation:
PMID:  16437513     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Acid reflux is a common problem, and is thought to occur in 4% to 10% of patients presenting to ENT clinics. A recent study of reflux and voice disorders suggests that up to 55% of patients with hoarseness (dysphonia) have laryngopharyngeal reflux. Anti-reflux therapy is often used empirically in treating patients with hoarseness, where no other cause has been identified by examination.
OBJECTIVES: The aim of the review was to assess the effectiveness of anti-reflux therapy for patients with hoarseness, in the absence of other identifiable causes, whether or not a definitive diagnosis of laryngopharyngeal and gastro-oesophageal reflux has been made. This was assessed by evaluation of prospective randomised controlled studies that were identified by a systematic review of the literature. Both medical and surgical treatments were evaluated.
SEARCH STRATEGY: The Cochrane ENT Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL) (Cochrane Library Issue 3, 2005), MEDLINE (1966 to 2005), EMBASE (1974 to 2005) and conference proceedings were searched with prespecified terms. The date of the last search was September 2005.
SELECTION CRITERIA: Randomised controlled trials recruiting patients with hoarseness in the absence of other identifiable causes, such as malignancy, cord palsy or nodules, whether or not a definitive diagnosis of laryngopharyngeal and gastro-oesophageal reflux has been made.
DATA COLLECTION AND ANALYSIS: Three reviewers examined the search results and identified studies before deciding which would be included in the review.
MAIN RESULTS: 302 potential studies were identified by the search strategy. No trials were identified which met our inclusion criteria. Six randomised controlled trials were identified in which some, but not all patients presented with hoarseness, and were treated with proton pump inhibition. As we could not determine with certainty whether all these patients had hoarseness among the other laryngeal symptoms, these were excluded. However, these studies suggest a significant placebo response, which is comparable to the benefit derived from anti-reflux therapy in some studies. As no trials met our criteria, we are unable to reach any firm conclusions regarding the effectiveness of anti-reflux treatment for hoarseness.
AUTHORS' CONCLUSIONS: There is a need for high quality randomised controlled trials to evaluate the effectiveness of anti-reflux therapy for patients with hoarseness which may be due to laryngopharyngeal and gastro-oesophageal reflux.
C Hopkins; U Yousaf; M Pedersen
Related Documents :
8830203 - Reproducibility of postoperative courses after surgical removal of symmetrically impact...
12706733 - Humidification in the long-term ventilated patient; a systematic review.
22325333 - Window replacement and residential lead paint hazard control 12 years later.
Publication Detail:
Type:  Journal Article; Review     Date:  2006-01-25
Journal Detail:
Title:  The Cochrane database of systematic reviews     Volume:  -     ISSN:  1469-493X     ISO Abbreviation:  Cochrane Database Syst Rev     Publication Date:  2006  
Date Detail:
Created Date:  2006-01-26     Completed Date:  2006-04-07     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  100909747     Medline TA:  Cochrane Database Syst Rev     Country:  England    
Other Details:
Languages:  eng     Pagination:  CD005054     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Gastroesophageal Reflux / complications,  drug therapy*
Gastrointestinal Agents / therapeutic use
Histamine H2 Antagonists / therapeutic use
Hoarseness / drug therapy*,  etiology
Proton Pumps / therapeutic use
Reg. No./Substance:
0/Gastrointestinal Agents; 0/Histamine H2 Antagonists; 0/Proton Pumps

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Perioperative blood transfusions for the recurrence of colorectal cancer.
Next Document:  Gonadotrophins for idiopathic male factor subfertility.